Neuromyelitis optica after Japanese encephalitis vaccination

European Journal of Neurology

Volumn 18, Issue 2, 2011, Pages

  Furukawa, Y ^a   Komai, K ^a   Yamada, M ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Japanese encephalitis; Neuromyelitis optica; Vaccination

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; STEROID;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; HUMAN; JAPANESE ENCEPHALITIS; LABORATORY TEST; LETTER; MALE; MYELOOPTIC NEUROPATHY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; VACCINATION; VISUAL IMPAIRMENT;

ADOLESCENT; ADRENAL CORTEX HORMONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPANESE ENCEPHALITIS VACCINES; MALE; NEUROMYELITIS OPTICA; VACCINATION;

EID: 78751522456     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03204.x     Document Type: Letter

References (5)

1. Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000; 18: 2963-2969.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
4. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis. Clinical, neuroimaging and immunogenetic studies. Brain 1999; 122: 1689-1696.
5. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370: 1847-1853.